Pfizer INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
PFE
Pfizer INCPfizer Inc. has reported a beneficial ownership of 3,442,940 shares, representing 3.3% of the outstanding common stock of ORIC Pharmaceuticals, Inc. as of March 31, 2026.
NYSE
PFE
Pfizer INCThe Vanguard Group has reported zero beneficial ownership in Pfizer Inc. common stock following an internal realignment that disaggregated reporting responsibilities.
NYSE
PFE
Pfizer INCPfizer Inc. has filed an amended Schedule 13G, disclosing a 2.3% beneficial ownership in Q32 Bio Inc., following a merger involving Homology Medicines.
NYSE
PFE
Pfizer INCPfizer Inc. and its affiliate, Pfizer Ventures (US) LLC, filed an amended Schedule 13G, disclosing a combined beneficial ownership of 3.0% in NEXTCURE, INC. common stock as of December 31, 2025.
NYSE
PFE
Pfizer INCPfizer Inc. has reported a 4.6% beneficial ownership stake in Zura Bio Limited's Class A Ordinary Shares as of December 31, 2024, according to a recent SEC Schedule 13G filing.
NYSE
PFE
Pfizer INCSCHEDULE 13G/A: Pfizer Discloses 3.6% Stake in Cardiff Oncology, Inc. via Amended Schedule 13G Filing
Pfizer Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 3.6% of Cardiff Oncology, Inc.'s common stock as of December 31, 2024.